Status:
COMPLETED
Trial of Adherence App for Buprenorphine Treatment (TAAB) Study
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
emocha Mobile Health, Inc.
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to pilot test a smartphone application that allows video-based directly observed therapy for participants receiving buprenorphine treatment for opioid use disorder in offi...
Detailed Description
The objective of this study is to compare an innovative mobile health (mHealth) platform to support participants being treated for opioid use disorder (OUD) with buprenorphine to treatment-as-usual (T...
Eligibility Criteria
Inclusion
- ≥18 years old
- Receiving buprenorphine treatment at an office-based buprenorphine program for ≤4 weeks
- Willing to be randomized to either VDOT or TAU
Exclusion
- Unable or unwilling to use smart phone
- Cognitive impairment resulting in inability to provide informed consent
- Researcher's discretion that participant will not be appropriate for participation in the study (e.g. participant is planning on moving away, is knowledgeable of future incarceration during the study, or has behavioral issues that may pose safety concerns for clinic and research staff)
- Inability to read and understand English as needed for following app instructions
Key Trial Info
Start Date :
February 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 29 2020
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT03779997
Start Date
February 15 2019
End Date
July 29 2020
Last Update
October 6 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston University
Boston, Massachusetts, United States, 02118
2
University of Washington
Seattle, Washington, United States, 98104